definiens: shall mean the achievement of either : ( i ) the prospectively define d primary efficacy endpoint(s ) in the Phase IIa Trial is / are met with statistical significance, and ther e are no adverse events in the trial that were ruled by the investigator(s ) as, or related to study medication, and no serious adverse events in such trial, or ( ii ) for the 10 consecutive ( as defined in the Series E Certificate of Designations ) commencing on and including the first full Tradin g Day following the public announcement of the results of the Phase IIa Trial, defined in the Asset Purchase Agreement, and ending on and including the tenth fu ll Trading Day following such announcement, the Clo sing Sales Price ( as defined in the Series E Certificate of Designations ) is greater than the Conversion Pr ice, then in effect ( as defined in the Series E Certificate of D esignations ), on each such Trading Day, by an amoun t greater than 500 % of such Conversion Price on such Trading Day